Treatment of Polydrug-Using Opiate Dependents During Withdrawal
|ClinicalTrials.gov Identifier: NCT00367874|
Recruitment Status : Completed
First Posted : August 23, 2006
Last Update Posted : August 23, 2006
Managed detoxification is a first and necessary step prior to treatment and rehabilitation. Detoxification can be a major obstacle for some patients, and the availability of managed and safe withdrawal is a prerequisite for long-term treatment.
In our clinical practice we have felt the need for a standardised and safe detoxification treatment regimen for our opioid addicts, as dependence on multiple drugs is so common.
- To assess whether a novel standardised treatment regimen - Buprenorphine (BPN) combined with Valproate (VPA) - will result in fewer withdrawal symptoms during detoxification of opiate–polydrug users than the existing treatment regimen, i.e. Clonidine (CLN) combined with Carbamazepine (CBZ).
- To determine whether there are differences in treatment retention between the BPN/VPA and the CLN/CBZ groups.
- To assess differences in clinical side-effects and biochemical interactions between the two treatment regimens.
|Condition or disease||Intervention/treatment||Phase|
|Opiate Dependence Drug Dependence Substance Withdrawal Syndrome||Drug: Buprenorphine Drug: Valproate||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Treatment of Polydrug-Using Opiate Dependents During Withdrawal|
|Study Start Date :||February 2003|
|Study Completion Date :||November 2003|
- Retention in treatment
- Withdrawal symptoms
- Serum concentration of Valproate and Buprenorphine separately and in combination
- Urine testing
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00367874
|Sorlandet Hospital HF, Addiction Unit (ARA)|
|Kristiansand, Vest-Agder, Norway, N-4604|
|Principal Investigator:||Oistein Kristensen, MD||Sorlandet Hospital HF, Addiction Unit|